Extensive evidence suggest that dysregulation of AMPK is associated with these metabolic disorders, and that modulation of AMPK activation, either through excise or by pharmacological AMPK activators, could be used to treat or prevent these diseases52. The gene discussed is PRKAA2; the disease is metabolic disease.